



Grant Number: 1R01HL112640-01A1

Principal Investigator(s):

DAVID R MANKA, PHD
NEAL L WEINTRAUB (contact), MD

Project Title: Perivascular adipose tissue and vascular remodeling

Ms. Mary Z. Ucci
Director Business Affairs
University of Cincinnati
UNIV HALL
P. O. Box 210222
Cincinnati, OH 45221

Award e-mailed to: ospaward@uc.edu

Budget Period: 07/13/2012 – 06/30/2013

Project Period: 07/13/2012 – 06/30/2017

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$459,820 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF CINCINNATI in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R01HL112640. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the 1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Norma DeGuzman
Grants Management Officer
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 1R01HL112640-01A1**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$160,960
Fringe Benefits	\$47,919
Supplies	\$80,000
Travel Costs	\$4,000

Federal Direct Costs	\$292,879
Federal F&A Costs	\$166,941
Approved Budget	\$459,820
Federal Share	\$459,820
TOTAL FEDERAL AWARD AMOUNT	\$459,820

AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$459,820
--	------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$459,820	\$459,820
2	\$451,185	\$451,185
3	\$444,120	\$444,120
4	\$435,485	\$435,485
5	\$427,635	\$427,635

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number: 93.837

EIN: 1316000989A1

Document Number: RHL112640A

Fiscal Year: 2012

IC	CAN	2012	2013	2014	2015	2016
HL	8475146	\$459,820	\$451,185	\$444,120	\$435,485	\$427,635

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: HHVBN / OC: 414A / Processed: DEGUZMANN 07/05/2012

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01HL112640-01A1

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 1R01HL112640-01A1

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase V Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Treatment of Program Income:
Additional Costs

SECTION IV – HL Special Terms and Conditions – 1R01HL112640-01A1

NHLBI OPERATING GUIDELINES

Funding of this award is in accordance with the NHLBI FY 2012 Operating Guidelines, which can be found at: <http://www.nhlbi.nih.gov/funding/policies/operguid.htm>

BUDGET PERIOD

This award is issued for less than a 12-month budget period in order to distribute future noncompeting awards more evenly throughout the fiscal year. Any subsequent noncompeting budget period(s) will begin on July 1 and will be 12 months in duration. The project period end date has been adjusted accordingly.

MULTIPLE PI - Prior Approvals

In keeping with NOT-OD-06-054 (<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-054.html>), as this grant has multiple Principal Investigators (PIs), although the signatures of the PIs are not required on prior approval requests submitted to the agency, the grantee institution must secure and retain the signatures of all of the PIs within their own internal processes.

NHLBI ADJUSTMENTS FOR SALARY BASED AWARDS

Salary funds provided on NHLBI research grants will be adjusted if investigators receive career-type salary based awards. Examples of such awards include the Independent Scientist Award (K02, formerly K04) and other similar awards as described in the November 1993 Circulation article (Vol. 88, No. 5, Part 1). In the event that such an award is made for an investigator receiving salary support from an NHLBI grant, the Institute must be informed in writing within 30 days from the start date of the award so that any required adjustment can be made.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These

individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Norma Deguzman

Email: deguzman@nhlbi.nih.gov **Phone:** 301-496-6740 **Fax:** 301-451-5461

Program Official: Yunling Gao

Email: gaoy2@nhlbi.nih.gov **Phone:** 301-435-0560 **Fax:** 301-480-2858

SPREADSHEET SUMMARY

GRANT NUMBER: 1R01HL112640-01A1

INSTITUTION: UNIVERSITY OF CINCINNATI

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
Salaries and Wages	\$160,960	\$160,960	\$160,960	\$160,960	\$160,960
Fringe Benefits	\$47,919	\$47,919	\$47,919	\$47,919	\$47,919
Supplies	\$80,000	\$74,500	\$70,000	\$62,500	\$53,500
Travel Costs	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000
Other Costs				\$2,000	\$6,000
TOTAL FEDERAL DC	\$292,879	\$287,379	\$282,879	\$277,379	\$272,379
TOTAL FEDERAL F&A	\$166,941	\$163,806	\$161,241	\$158,106	\$155,256
TOTAL COST	\$459,820	\$451,185	\$444,120	\$435,485	\$427,635

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	57%	57%	57%	57%	57%
F&A Cost Base 1	\$292,879	\$287,379	\$282,879	\$277,379	\$272,379
F&A Costs 1	\$166,941	\$163,806	\$161,241	\$158,106	\$155,256



NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

Grant Number: 1R01AR070029-01
FAIN: R01AR070029

Principal Investigator(s):
Muhammad Ashraf, PHD
YAO LIANG TANG (contact), MD
Neal L Weintraub, MD

Project Title: Innovative Approaches to Treat Duchenne Muscular Dystrophy Using iPSC-Derived Muscle Progenitors

White, Sarah J.
Executive Director
1120 15th Street, CJ-3301
Augusta, GA 309124810

Award e-mailed to: ogc@gru.edu

Period Of Performance:
Budget Period: 04/01/2016 – 03/31/2017
Project Period: 04/01/2016 – 03/31/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$528,394 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to GEORGIA REGENTS RESEARCH INSTITUTE, INC in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Arthritis And Musculoskeletal And Skin Diseases of the National Institutes of Health under Award Number R01AR070029. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Andrew Jones
Grants Management Officer
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

Additional information follows

SECTION I – AWARD DATA – 1R01AR070029-01**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$106,418
Fringe Benefits	\$36,182
Personnel Costs (Subtotal)	\$142,600
Materials & Supplies	\$37,629
Travel	\$2,640
Other	\$26,400
Subawards/Consortium/Contractual Costs	\$179,916
Publication Costs	\$2,640
Equipment or Facility Rental/User Fees	\$8,800

Federal Direct Costs	\$400,625
Federal F&A Costs	\$127,769
Approved Budget	\$528,394
Total Amount of Federal Funds Obligated (Federal Share)	\$528,394
TOTAL FEDERAL AWARD AMOUNT	\$528,394

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$528,394

SUMMARY TOTALS FOR ALL YEARS			
YR	THIS AWARD		CUMULATIVE TOTALS
1		\$528,394	\$528,394
2		\$541,817	\$541,817
3		\$528,617	\$528,617
4		\$515,417	\$515,417
5		\$515,417	\$515,417

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name: Arthritis, Musculoskeletal and Skin Diseases Research
CFDA Number: 93.846
EIN: 1581418202A1
Document Number: RAR070029A
PMS Account Type: P (Subaccount)
Fiscal Year: 2016

IC	CAN	2016	2017	2018	2019	2020
AR	8472466	\$528,394	\$541,817	\$528,617	\$515,417	\$515,417

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: 2 B / **OC:** 414A / **Released:** JONESAN 02/22/2016
Award Processed: 02/25/2016 12:02:18 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01AR070029-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 1R01AR070029-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.

- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AR070029. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements

and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

SECTION IV – AR Special Terms and Conditions – 1R01AR070029-01

COMPETING FUNDING LEVEL

This award includes funding adjustments in accordance with current NIAMS FY2016 policy.

CONSORTIUM/CONTRACTUAL COSTS

This award includes funds awarded for consortium activity with the University of Illinois at Chicago. Consortia are to be established and administered as described in the NIH Grants Policy Statement.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Steve Austin
Email: austins2@mail.nih.gov **Phone:** 301-594-3504 **Fax:** 301-480-5450

Program Official: Thomas Cheever
Email: thomas.cheever@nih.gov **Phone:** 301-594-5019 **Fax:** 301-480-1284

SPREADSHEET SUMMARY

GRANT NUMBER: 1R01AR070029-01

INSTITUTION: GEORGIA REGENTS RESEARCH INSTITUTE, INC

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
Salaries and Wages	\$106,418	\$106,418	\$106,418	\$106,418	\$106,418
Fringe Benefits	\$36,182	\$36,182	\$36,182	\$36,182	\$36,182
Personnel Costs (Subtotal)	\$142,600	\$142,600	\$142,600	\$142,600	\$142,600
Equipment		\$26,400	\$13,200		
Materials & Supplies	\$37,629	\$37,629	\$37,629	\$37,629	\$37,629
Travel	\$2,640	\$2,640	\$2,640	\$2,640	\$2,640
Other	\$26,400	\$26,400	\$26,400	\$26,400	\$26,400
Subawards/Consortium/Contractual Costs	\$179,916	\$179,939	\$179,939	\$179,939	\$179,939
Publication Costs	\$2,640	\$2,640	\$2,640	\$2,640	\$2,640
Equipment or Facility Rental/User Fees	\$8,800	\$8,800	\$8,800	\$8,800	\$8,800
TOTAL FEDERAL DC	\$400,625	\$427,048	\$413,848	\$400,648	\$400,648
TOTAL FEDERAL F&A	\$127,769	\$114,769	\$114,769	\$114,769	\$114,769
TOTAL COST	\$528,394	\$541,817	\$528,617	\$515,417	\$515,417

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	52%	52%	52%	52%	52%

F&A Cost Base 1	\$245,709	\$220,709	\$220,709	\$220,709	\$220,709
F&A Costs 1	\$127,769	\$114,769	\$114,769	\$114,769	\$114,769



NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Grant Number: 1R01HL126949-01A1
FAIN: R01HL126949

Principal Investigator(s):
Neal L Weintraub, MD

Project Title: Epigenetic regulation of HDAC9 in obesity and atherosclerosis

White, Sarah J.
Executive Director
Georgia Regents Research Institute, Inc.
1120 15th Street, CJ-3301
Augusta, GA 309124810

Award e-mailed to: ogc@gru.edu

Period Of Performance:

Budget Period: 03/01/2016 – 02/28/2017

Project Period: 03/01/2016 – 02/29/2020

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$448,400 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to GEORGIA REGENTS RESEARCH INSTITUTE, INC in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R01HL126949. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

John Diggs
Grants Management Officer
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 1R01HL126949-01A1**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$141,290
Fringe Benefits	\$48,038
Personnel Costs (Subtotal)	\$189,328
Materials & Supplies	\$40,268
Travel	\$3,000
Other	\$40,000
Subawards/Consortium/Contractual Costs	\$19,404
Publication Costs	\$3,000

Federal Direct Costs	\$295,000
Federal F&A Costs	\$153,400
Approved Budget	\$448,400
Total Amount of Federal Funds Obligated (Federal Share)	\$448,400
TOTAL FEDERAL AWARD AMOUNT	\$448,400

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$448,400

SUMMARY TOTALS FOR ALL YEARS			
YR	THIS AWARD		CUMULATIVE TOTALS
1		\$448,400	\$448,400
2		\$441,220	\$441,220
3		\$438,310	\$438,310
4		\$438,310	\$438,310

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name: Cardiovascular Diseases Research
CFDA Number: 93.837
EIN: 1581418202A1
Document Number: RHL126949A
PMS Account Type: P (Subaccount)
Fiscal Year: 2016

IC	CAN	2016	2017	2018	2019
HL	8475146	\$448,400	\$441,220	\$438,310	\$438,310

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: HHAATN / **OC:** 414A / **Released:** DIGGSJ 02/22/2016
Award Processed: 02/25/2016 12:09:23 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01HL126949-01A1

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 1R01HL126949-01A1

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01HL126949. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

SECTION IV – HL Special Terms and Conditions – 1R01HL126949-01A1**NHLBI OPERATING GUIDELINES**

This award is being issued in accordance with the NHLBI FY 2016 Operating Guidelines, which can be found at: <https://www.nhlbi.nih.gov/research/funding/general/current-operating-guidelines>

FUTURE BUDGET PERIOD SUPPORT

In accordance with the NIH requirement to maintain an overall average of 4.0 years, the competing segment for this grant is being reduced by 1 budget period.

PRIOR APPROVAL

Per request from Sandy Ferguson at Georgia Regents University Medical College of Georgia on February 17, 2016, Dr Tapan Chatterjee has been removed as a multi-PI on this award and this is now recognized as a single PI award.

CONSORTIUM/CONTRACTUAL COSTS

This award includes funds awarded for consortium activity with the University of Cincinnati. The recipient, as the direct and primary recipient of NIH grant funds, is accountable to NIH for the performance project, the appropriate expenditures of grant funds by all parties, and all other obligations of the recipient, as specified in the NIH Grants Policy Statement. In general, the requirements that apply to the recipient, including the intellectual property requirements also apply to consortium participant (s)

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Erin A Davis
Email: davisea@mail.nih.gov **Phone:** 301-402-3839

Program Official: Michelle Olive
Email: olivem@mail.nih.gov **Phone:** 301-443-7933

SPREADSHEET SUMMARY

GRANT NUMBER: 1R01HL126949-01A1

INSTITUTION: GEORGIA REGENTS RESEARCH INSTITUTE, INC

Budget	Year 1	Year 2	Year 3	Year 4
Salaries and Wages	\$141,290	\$141,290	\$141,290	\$141,290
Fringe Benefits	\$48,038	\$48,038	\$48,038	\$48,038
Personnel Costs (Subtotal)	\$189,328	\$189,328	\$189,328	\$189,328
Materials & Supplies	\$40,268	\$40,268	\$40,268	\$40,268
Travel	\$3,000	\$3,000	\$3,000	\$3,000
Other	\$40,000	\$40,000	\$40,000	\$40,000
Subawards/Consortium/Contractual Costs	\$19,404	\$19,404	\$19,404	\$19,404
Publication Costs	\$3,000	\$3,000	\$3,000	\$3,000
TOTAL FEDERAL DC	\$295,000	\$295,000	\$295,000	\$295,000
TOTAL FEDERAL F&A	\$153,400	\$146,220	\$143,310	\$143,310
TOTAL COST	\$448,400	\$441,220	\$438,310	\$438,310

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4
F&A Cost Rate 1	52%	52%	52%	52%
F&A Cost Base 1	\$295,000	\$281,192	\$275,596	\$275,596
F&A Costs 1	\$153,400	\$146,220	\$143,310	\$143,310